nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-211-3-22-27nogr-2331Research ArticleПЕРЕДОВАЯ СТАТЬЯLEADING ARTICLEМетастатический колоректальный ракMetastatic colorectal cancerhttps://orcid.org/0000-0003-4424-0850ЦыганковаМ. В.TsygankovaM. V.tsygankovva98@mail.ruhttps://orcid.org/0000-0001-6375-8335ТкаченкоЕ. В.TkachenkoE. V.noemail@neicon.ruФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Петрова» Минздрава РоссииРоссияN. N. Petrov National Medical Research Center of OncologyRussian Federation202325072023032227Copyright © Цыганкова М.В., Ткаченко Е.В., 20232023Цыганкова М.В., Ткаченко Е.В.Tsygankova M.V., Tkachenko E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2331

В данной статье представлен клинический случай пациента с колоректальным раком (КРР), который был диагностирован на этапе метастатического генерализованного процесса, в связи с длительным бессимптомным течением, неспецифичностью симптомов и трудностью первичной диагностики. Рассматриваются особенности ведения, а также возможности лечения пациента с метастатическим колоректальным раком (мКРР) на современном этапе. Данное клиническое наблюдение демонстрирует актуальность поиска новых методов диагностики, схем лечения и принципов профилактики КРР.

This article presents a clinical case of a patient with colorectal cancer (CRC), who was diagnosed at the stage of a metastatic generalized process, due to a long asymptomatic course, non-specific symptoms and the difficulty of primary diagnosis. The features of management, as well as the possibilities of treating a patient with metastatic colorectal cancer (mCRC) at the present stage, are considered. This clinical observation demonstrates the relevance of the search for new diagnostic methods, treatment regimens and principles for the prevention of CRC.

метастатический колоректальный раклекарственная терапияКРРмКРРклинический случайmetastatic colorectal cancerdrug therapyCRRmCRCclinical caseReferencesSung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660.Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660.Kaprin A. D., Starinskiy V. V., Petrova G. V. Malignant neoplasms in Russia in 2017. Moscow, 2018. (In Russ.)@@ Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2017 г. - Москва, 2018.Kaprin A. D., Starinskiy V. V., Petrova G. V. Malignant neoplasms in Russia in 2017. Moscow, 2018. (In Russ.)@@ Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2017 г. - Москва, 2018.Krzystek-Korpacka M., Zawadzki M., Kapturkiewicz B. et al. Subsite heterogeneity in the profiles of circulating cytokines in colorectal cancer. Cytokine. 2018 Oct;110:435-441. doi: 10.1016/j.cyto.2018.05.015.Krzystek-Korpacka M., Zawadzki M., Kapturkiewicz B. et al. Subsite heterogeneity in the profiles of circulating cytokines in colorectal cancer. Cytokine. 2018 Oct;110:435-441. doi: 10.1016/j.cyto.2018.05.015.Tsukanov A. S., Shelygin Yu.A., Frolov S. A. et al. [Recommendations for the selection of patients for molecular genetic diagnosis of Lynch syndrome]. Guidelines. Moscow, 2019. (in Russ.)@@ Цуканов А. С., Шелыгин Ю. А., Фролов С. А. и др. Рекомендации по отбору пациентов для молекулярно-генетической диагностики синдрома Линча. Методические рекомендации. - Москва, 2019.Tsukanov A. S., Shelygin Yu.A., Frolov S. A. et al. [Recommendations for the selection of patients for molecular genetic diagnosis of Lynch syndrome]. Guidelines. Moscow, 2019. (in Russ.)@@ Цуканов А. С., Шелыгин Ю. А., Фролов С. А. и др. Рекомендации по отбору пациентов для молекулярно-генетической диагностики синдрома Линча. Методические рекомендации. - Москва, 2019.Theodoratou E., Farrington S. M., Tenesa A. et al. Associations between dietary and lifestyle risk factors and colorectal cancer in the Scottish population. Eur J Cancer Prev. 2014;23:8-17. doi:10.1097/cej.0b013e3283639fb8.Theodoratou E., Farrington S. M., Tenesa A. et al. Associations between dietary and lifestyle risk factors and colorectal cancer in the Scottish population. Eur J Cancer Prev. 2014;23:8-17. doi:10.1097/cej.0b013e3283639fb8.Rasool S., Kadla S. A., Rasool V., et al. A comparative overview of general risk factors associated with the incidence of colorectal cancer. Tumor Biol. 2013;34:2469-76. doi:10.1007/s13277-013-0876-y.Rasool S., Kadla S. A., Rasool V., et al. A comparative overview of general risk factors associated with the incidence of colorectal cancer. Tumor Biol. 2013;34:2469-76. doi:10.1007/s13277-013-0876-y.Esposito K., Chiodini P., Capuano A. et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine. 2013;44:634-47. doi:10.1007/s12020-013-9939-5.Esposito K., Chiodini P., Capuano A. et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine. 2013;44:634-47. doi:10.1007/s12020-013-9939-5.Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660.Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660.Malvezzi M., Carioli G., Bertuccio P. et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol. 2018;29:1016-1022. doi:10.1093/annonc/mdy033.Malvezzi M., Carioli G., Bertuccio P. et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol. 2018;29:1016-1022. doi:10.1093/annonc/mdy033.Osterlund P., Salminen T., Soveri L. M., et al.; Members of The RAXO study group are collaborators of this study and are listed in Appendix Table 4B. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study. Lancet Reg Health Eur. 2021 Jan 29;3:100049. doi: 10.1016/j.lanepe.2021.100049.Osterlund P., Salminen T., Soveri L. M., et al.; Members of The RAXO study group are collaborators of this study and are listed in Appendix Table 4B. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study. Lancet Reg Health Eur. 2021 Jan 29;3:100049. doi: 10.1016/j.lanepe.2021.100049.Lévi F. A., Boige V., Hebbar M. et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2016;27:267-274. doi:10.1093/annonc/mdv548.Lévi F. A., Boige V., Hebbar M. et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2016;27:267-274. doi:10.1093/annonc/mdv548.Modest D. P. Denecke T. Pratschke J. et al. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. Eur J Cancer. 2018;88:77-86. doi:10.1016/j.ejca.2017.10.028.Modest D. P. Denecke T. Pratschke J. et al. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. Eur J Cancer. 2018;88:77-86. doi:10.1016/j.ejca.2017.10.028.[Malignant neoplasms of the colon and rectosigmoid]. Clinical guidelines. 2020, pp. 1-70. (in Russ.)@@ Клинические рекомендации - Злокачественные новообразования ободочной кишки и ректосигмоидного отдела - 2020. С. 1-70.[Malignant neoplasms of the colon and rectosigmoid]. Clinical guidelines. 2020, pp. 1-70. (in Russ.)@@ Клинические рекомендации - Злокачественные новообразования ободочной кишки и ректосигмоидного отдела - 2020. С. 1-70.

The authors declare that there are no conflicts of interest present.